AZ trumpets tezepelumab data as filing for severe asthma loomsAstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to Share XAZ trumpets tezepelumab data as filing for severe asthma loomshttps://pharmaphorum.com/news/az-trumpets-tezepelumab-data-as-filing-for-severe-asthma-looms/
Tribal Health appoints Niaz Rizwani as strategy directorTribal Health has appointed Niaz Rizwani as strategy director, joining from Publicis Health where he was a senior Share XTribal Health appoints Niaz Rizwani as strategy directorhttps://pharmaphorum.com/news/tribal-health-appoints-niaz-rizwani-as-strategy-director/
Healthcare’s digital transformation began within weeks of pandemic – reportHealthcare organisations that have been traditionally slow to adopt new technology produced a response to the pandemic that Share XHealthcare’s digital transformation began within weeks of pandemic – reporthttps://pharmaphorum.com/news/healthcares-digital-transformation-began-within-weeks-of-pandemic-report/
NICE okays regular NHS funding for Novartis’ breast cancer drug KisqaliNICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously Share XNICE okays regular NHS funding for Novartis’ breast cancer drug Kisqalihttps://pharmaphorum.com/news/nice-okays-regular-nhs-funding-for-novartis-breast-cancer-drug-kisqali/
Tribunal maintains Lexon’s £1.2m fine for breaking competition lawPharmaceutical wholesaler Lexon (UK) has lost its appeal against a £1.2 million fine in a case that accused Share XTribunal maintains Lexon’s £1.2m fine for breaking competition lawhttps://pharmaphorum.com/news/tribunal-maintains-lexons-1-2m-fine-for-breaking-competition-law/
Altimmune begins trial of nasal vaccine for COVID-19Pfizer/BioNTech’s mRNA vaccine against COVID is a technical marvel – but the ultra-cool temperatures required for storage and Share XAltimmune begins trial of nasal vaccine for COVID-19https://pharmaphorum.com/news/altimmune-begins-trial-of-nasal-vaccine-for-covid-19/
Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buyMerck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for Share XMerck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buyhttps://pharmaphorum.com/news/merck-takes-on-lilly-nektar-in-il-2-with-1-85bn-pandion-buy/
Otsuka, Click trial digital depression therapy with GoogleOtsuka and Click Therapeutics are working with Verily, the healthcare subsidiary of Google owners Alphabet, on a fully Share XOtsuka, Click trial digital depression therapy with Googlehttps://pharmaphorum.com/news/otsuka-click-trial-digital-depression-therapy-with-google/
Switch data back Chiesi/Protalix long-acting Fabry drugChiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102, Share XSwitch data back Chiesi/Protalix long-acting Fabry drughttps://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/
